Keith Murphy is currently CEO and Chairman of Viscient Bio, Inc., and a serial entrepreneur and investor in biotech.  Prior to co-founding Viscient Biosciences, Mr. Murphy founded Organovoin 2007 and led all company operations until 2017.  He co-invented the NovoGen MMX bioprinter platform and grew Organovo through early investments and pharma corporate partnerships  Prior to Organovo, Mr. Murphy spent ten years at Amgen in roles of increasing responsibility, including four years as the Global Operations Leader of denosumab, now marketed as Prolia & Xgeva ($4B+ annual sales).  Prior to Amgen, he played a key role at Alkermes (NASDAQ:ALKS) in the successful development of once-monthly human growth hormone (hGH) in partnership with Genentech.  He holds a B.S. in Chemical Engineering from the Massachusetts Institute of Technology and is an alumnus of the UCLA Anderson School of Management.  Mr. Murphy serves as co-chair of the Board of No Patient Left Behind, and on the Board of Directors of the California Life Sciences Association, the state’s life science industry public policy, advocacy and business leadership organization.